Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock [Yahoo! Finance]
Kodiak Sciences Inc (KOD)
Last kodiak sciences inc earnings: 11/12 05:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Kodiak's lead medicine, tarcocimab, is being studied in two Phase 3 trials for retinal diseases and has shown strong potential. The company's stock is considered undervalued with a market cap of $400 million and is expected to climb to $20 or a $1 billion+ market cap as Phase 3 results approach. Upcoming data and trials, including Phase IB data for macular edema secondary to inflammation, are expected to drive growth and reduce risks. The stock has gained 28.4% and is expected to have multiple drivers for growth and potential upside. Jefferies has upgraded Kodiak Sciences Inc. (NASDAQ: KOD ), a biopharmaceutical company focused on retinal (eye) diseases. Kodiak's lead investigational medicine, tarcocimab, is an anti-VEGF antibody biopolymer conjugate under development for high-prevalence retinal vascular diseases. Tarcocimab is currently being studied in two Phase 3 trials, GLOW2 in diabetic retinopathy and DAYBREAK in patients with wet age-related macular degeneration (wet AMD)
Show less
Read more
Impact Snapshot
Event Time:
KOD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KOD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KOD alerts
High impacting Kodiak Sciences Inc news events
Weekly update
A roundup of the hottest topics
KOD
News
- KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential [Yahoo! Finance]Yahoo! Finance
- Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases [Yahoo! Finance]Yahoo! Finance
- Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic DiseasesPR Newswire
- Kodiak Sciences Inc. (NASDAQ: KOD) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock.MarketBeat
- Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy? [Yahoo! Finance]Yahoo! Finance
KOD
Earnings
- 11/14/24 - Beat
KOD
Sec Filings
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- KOD's page on the SEC website